|
1) Freeman SD, Kelm S, Barber EK, et al. Characterization of CD33 as a new member of the sialoadesin family of cellular interaction molecules. Blood. 1995; 85: 2005-12
|
|
|
|
2) Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chem. 2002; 13: 47-58
|
|
|
|
|
|
3) Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Phamacol. 2001; 41: 1206-14
|
|
|
|
|
|
4) Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005; 19: 176-82
|
|
|
|
|
5) Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000; 14: 1436-43
|
|
|
|
|
|
6) Matsui H, Takeshita A, Naito K, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia. 2002; 16: 813-9
|
|
|
|
|
|
7) Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005; 104: 1442-52
|
|
|
|
|
|
8) 吉場史朗, 堀田知光, 飛内賢正, 他. 急性骨髄性白血病(AML)に対するCMA676の有効性と安全性の評価−第2相臨床試験の報告. 臨床血液. 2005; 46: 733. abstr. #WS2-2
|
|
|
|
|
|
9) Tsimberidou AM, Estey E, Cortes JE, et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 2003; 52: 449-52
|
|
|
|
|
|
10) Cortes J, Tsimberidou AM, Alvarez R, et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol. 2002; 50: 497-500
|
|
|
|
|
|
11) Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol. 2003; 51: 87-90
|
|
|
|
|
|
12) Apostolidou E, Cortes J, Tsimberidou A, et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res. 2003; 27: 887-91
|
|
|
|
|
|
13) Chevallier P, Roland V, Mahe B, et al. Administration of Mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33＋ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2005; 29: 1003-7
|
|
|
|
|
|
14) Stone RM, Moser B, Schulman P, et al. A dose escalation and phase II study of gemtuzumab ozogamicin (GO) with high-dose cytarabine (HiDAC) for patients (pts) with refractory or relapsed acute myeloid leukemia (AML): CALGB 19902. Blood. 2004; 104: 249a
|
|
|
|
|
|
15) Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002; 99: 4343-9
|
|
|
|
|
|
16) Tsimberidou A, Estey E, Cortes J, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003; 97: 1481-7
|
|
|
|
|
|
17) DeAngelo DJ, Stone RM, Durrant S, et al. Gemtuzumab ozogamicin (Mylotarg) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: Two age-specific phase 2 trials. Blood. 2003; 102: 100a
|
|
|
|
|
|
18) Amadori S, Suciu S, Willemze R, et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica. 2004; 89: 950-6
|
|
|
|
|
|
19) Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003; 102: 4277-83
|
|
|
|
|
|
20) Rao AV, Rizzieri DA, Moore JO, et al. Feasibility study of dose dence induction regimen of high dose cytarabine (hiDAC) and gemtuzumab ozogamicin (Mylotarg) for newly diagnosed elderly patients with acute myeloid leukemia. Blood. 205; 106: 231b
|
|
|
|
|
|
21) Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology (Educational book of annual meeting of American Society of Hematology). 2005. p. 143-50
|
|
|
|
|
|
22) Burnett A, Kell W, Goldstone AH, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial. Blood. 2006; 108: 8a
|
|
|
|
|